NCT05515796 2026-04-01
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
Clinical Trials
30 trialsNCT05143970 2026-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Recruiting
NCT05187182 2026-03-18
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT06109467 2026-02-09
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06468280 2026-01-21
ROSETTE
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT07009600 2025-06-06
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Samsung Medical Center
Completed
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT02578368 2024-11-12
FLOT5
Krankenhaus Nordwest
Phase 3 Completed
NCT06121700 2023-11-08
Miracle-G
Fudan University
Phase 2 Recruiting
NCT04819971 2023-04-25
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04510285 2023-02-01
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT04168931 2023-01-17
GASTHER2
AC Camargo Cancer Center
Phase 2 Terminated
NCT04888663 2021-05-21
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
Phase 1/2 Unknown
NCT02901301 2021-04-06
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
Yonsei University
Phase 1/2 Unknown
NCT01359397 2021-01-27
B-DOCT
The Netherlands Cancer Institute
Phase 2 Unknown
NCT01928290 2020-08-25
FOLFIRINOX
Washington University School of Medicine
Phase 2 Completed
NCT02581462 2020-08-11
PETRARCA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2/3 Completed
NCT02726399 2020-01-21
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00515411 2019-12-10
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT01364493 2017-05-09
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Peking University
Phase 2 Completed
NCT03024450 2017-01-24
Trastuzumab Based Therapy in HER2 Positive AGC
Shanghai Zhongshan Hospital
Completed
NCT02004769 2016-11-18
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Sun Yat-sen University
Phase 2 Completed
NCT01228045 2016-06-22
A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
National University Hospital, Singapore
Phase 2 Unknown
NCT02030561 2016-06-22
NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
National University Hospital, Singapore
Phase 1/2 Unknown
NCT02805829 2016-06-22
Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
Xuzhou Medical University
Phase 1/2 Unknown
NCT02250209 2014-09-26
T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
Chinese PLA General Hospital
Phase 2 Unknown